HIV Stocks List

Recent Signals

Date Stock Signal Type
2021-04-14 AIM Stochastic Reached Oversold Weakness
2021-04-14 CEMI NR7 Range Contraction
2021-04-14 CEMI NR7-2 Range Contraction
2021-04-14 CEMI Narrow Range Bar Range Contraction
2021-04-14 CEMI Stochastic Reached Oversold Weakness
2021-04-14 CNCE Slingshot Bearish Bearish Swing Setup
2021-04-14 ENOB Shooting Star Candlestick Bearish
2021-04-14 GILD Bollinger Band Squeeze Range Contraction
2021-04-14 GILD Crossed Above 200 DMA Bullish
2021-04-14 GILD Crossed Above 20 DMA Bullish
2021-04-14 GOVX Fell Below 50 DMA Bearish
2021-04-14 GOVX 20 DMA Support Bullish
2021-04-14 GSK 20 DMA Resistance Bearish
2021-04-14 GSK Bollinger Band Squeeze Range Contraction
2021-04-14 LH MACD Bearish Signal Line Cross Bearish
2021-04-14 NNVC Narrow Range Bar Range Contraction
2021-04-14 NNVC 180 Bearish Setup Bearish Swing Setup
2021-04-14 NNVC NR7 Range Contraction
2021-04-14 NNVC 200 DMA Resistance Bearish
2021-04-14 OSUR Stochastic Buy Signal Bullish
2021-04-14 RPRX Cup with Handle Other
2021-04-14 RPRX Pocket Pivot Bullish Swing Setup
2021-04-14 THTX Fell Below 20 DMA Bearish
2021-04-14 THTX Slingshot Bullish Bullish Swing Setup
2021-04-14 TRIB Non-ADX 1,2,3,4 Bearish Bearish Swing Setup

Recent News for HIV Stocks

Date Stock Title
Apr 14 GILD U.S. in unique position to force increased accountability at the WHO: FDD
Apr 14 GSK U.S. in unique position to force increased accountability at the WHO: FDD
Apr 14 RPRX Insider Sells Royalty Pharma's Shares
Apr 14 THTX Theratechnologies Inc. (THTX) CEO Paul Levesque on Q1 2021 Results - Earnings Call Transcript
Apr 14 GSK Moderna is committed to keep chasing new COVID variants: CEO
Apr 14 GSK Is GSK Stock A Buy or Sell?
Apr 14 GILD Gilead (GILD) Gets FDA Nod for Trodelvy in Urothelial Cancer
Apr 14 GILD Gilead’s Bladder Cancer Drug Trodelvy Gets FDA Nod
Apr 14 GSK UK Trial On Mix-Match COVID-19 Vaccines Expanded To Add Moderna, Novavax Shots
Apr 14 THTX Theratechnologies EPS misses by $0.03, misses on revenue
Apr 14 THTX Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights
Apr 14 HTBX HTBX: Cash, COVID and Clinical Data
Apr 14 GILD A Peek Into The Markets: US Stock Futures Edge Higher; Bank Earnings In Focus
Apr 13 GILD U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
Apr 13 ENOB Enochian Biosciences: Small Biotech With Ambitious Goals In HIV And HBV
Apr 13 GILD Gilead wins FDA accelerated approval for Trodelvy in urothelial cancer
Apr 13 GILD How COVID-19 transformed the biotech industry
Apr 13 GILD Gilead halts remdesivir trial in high-risk COVID-19 patients
Apr 12 THTX Theratechnologies to Present at the Bloom Burton & Co. Healthcare Investor Conference
Apr 12 THTX Theratechnologies to Announce Financial Results for Its First Quarter Fiscal 2021

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. In most cases, HIV is a sexually transmitted infection and occurs by contact with or transfer of blood, pre-ejaculate, semen, and vaginal fluids. Non-sexual transmission can occur from an infected mother to her infant during pregnancy, during childbirth by exposure to her blood or vaginal fluid, and through breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.
HIV infects vital cells in the human immune system, such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including pyroptosis of abortively infected T cells, apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8+ cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections, leading to the development of AIDS.

More about HIV
Browse All Tags